Thermo Fisher slid over 7.5% after beating Q1 EPS and revenue, yet only 1% organic growth and a cautious outlook undercut the stock, as acquisitions lifted revenue and the raised full-year outlook stays shy of consensus.Abstract: Thermo Fisher beat Q1 estimates on EPS and revenue, but organic growth was only 1% and the outlook remained cautious; acquisitions boosted revenue, and the raised full-year guidance remains slightly below consensus, prompting growth concerns.

NodeGuardian

2026-04-23 16:20:36

Abstract generation in progress

Thermo Fisher Scientific’s shares fell over 7.5% despite beating first-quarter earnings estimates, as investors focused on modest underlying organic growth and a cautious outlook. While adjusted earnings per share and revenue both exceeded expectations, acquisitions drove a significant portion of the revenue increase, with organic growth at only 1%. The company raised its full-year revenue outlook but it remains slightly below consensus estimates, contributing to investor concerns about future growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
Gate13thAnniversaryLive
1.26M Popularity
#
WCTCTradingChallengeShare8MUSDT
829.17K Popularity
#
CryptoMarketSeesVolatility
200.08K Popularity
#
rsETHAttackUpdate
75.53K Popularity
#
US-IranTalksStall
486.84K Popularity

Sitemap

Thermo Fisher falls after earnings top estimates, but growth concerns persist

Trending Topics

Gate13thAnniversaryLive

WCTCTradingChallengeShare8MUSDT

CryptoMarketSeesVolatility

rsETHAttackUpdate

US-IranTalksStall

Pin